Clinical trial · no report yet · Phase 2
FITWISE
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- NCT06518837 ↗
- Recruiting
- Rutgers, The State University of New Jersey
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Arms
- Tirzepatide · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction)
- Sponsor
- Rutgers, The State University of New Jersey with Ludwig Institute for Cancer Research
- Start
- Oct 30, 2024
- Primary completion
- Sep 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06518837 · updated Jan 21, 2026